Radotinib

From WikiMD's Wellnesspedia

Radotinib is a drug used in the treatment of chronic myeloid leukemia (CML), a type of cancer that starts in certain blood-forming cells of the bone marrow. It is a second-generation tyrosine kinase inhibitor, which works by blocking certain proteins that can lead to the development of cancer cells.

Mechanism of Action[edit | edit source]

Radotinib inhibits BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). By doing so, it prevents the proliferation of cancer cells and induces apoptosis, or programmed cell death.

Clinical Use[edit | edit source]

Radotinib is approved for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive (Ph+) CML in patients who are resistant to or intolerant of at least one prior therapy, including imatinib.

Side Effects[edit | edit source]

Common side effects of radotinib include nausea, vomiting, diarrhea, and headache. Serious side effects may include myelosuppression, hepatotoxicity, and cardiac toxicity.

Development and Approval[edit | edit source]

Radotinib was developed by Il-Yang Pharm. Co., Ltd., a South Korean pharmaceutical company. It was approved for use in South Korea in 2012.

See Also[edit | edit source]


Radotinib Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD